nach oben

Diabetologia

Erschienen in:

01.10.2011 | Article

No evidence for a causal link between uric acid and type 2 diabetes: a Mendelian randomisation approach

verfasst von: R. Pfister, D. Barnes, R. Luben, N. G. Forouhi, M. Bochud, K.-T. Khaw, N. J. Wareham, C. Langenberg

Erschienen in: Diabetologia | Ausgabe 10/2011

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Epidemiological and experimental evidence suggests that uric acid has a role in the aetiology of type 2 diabetes. Using a Mendelian randomisation approach, we investigated whether there is evidence for a causal role of serum uric acid for development of type 2 diabetes.

Methods

We examined the associations of serum-uric-acid-raising alleles of eight common variants recently identified in genome-wide association studies and summarised this in a genetic score with type 2 diabetes in case–control studies including 7,504 diabetes patients and 8,560 non-diabetic controls. We compared the observed effect size to that expected based on: (1) the association between the genetic score and uric acid levels in non-diabetic controls; and (2) the meta-analysed uric acid level to diabetes association.

Results

The genetic score showed a linear association with uric acid levels, with a difference of 12.2 μmol/l (95% CI 9.3, 15.1) by score tertile. No significant associations were observed between the genetic score and potential confounders. No association was observed between the genetic score and type 2 diabetes with an OR of 0.99 (95% CI 0.94, 1.04) per score tertile, significantly different (p = 0.046) from that expected (1.04 [95% CI 1.03, 1.05]) based on the observed uric acid difference by score tertile and the uric acid to diabetes association of 1.21 (95% CI 1.14, 1.29) per 60 μmol/l.

Conclusions/interpretation

Our results do not support a causal role of serum uric acid for the development of type 2 diabetes and limit the expectation that uric-acid-lowering drugs will be effective in the prevention of type 2 diabetes.

Nur mit Berechtigung zugänglich

Kodama S, Saito K, Yachi Y et al (2009) Association between serum uric acid and development of type 2 diabetes. Diabetes Care 32:1737–1742PubMedCrossRef

Quinones GA, Natali A, Baldi S et al (1995) Effect of insulin on uric acid excretion in humans. Am J Physiol 268:E1–E5

Fox IH (1981) Metabolic basis for disorders of purine nucleotide degradation. Metabolism 30:616–634PubMedCrossRef

Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234PubMedCrossRef

Zhang W, Doherty M, Bardin T et al (2006) EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65:1312–1324PubMedCrossRef

Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403PubMedCrossRef

Sheehan NA, Didelez V, Burton PR, Tobin MD (2008) Mendelian randomisation and causal inference in observational epidemiology. PLoS Med 5:e177PubMedCrossRef

Smith GD, Ebrahim S (2003) “Mendelian randomization”: can genetic epidemiology contribute to understanding enviromental determinants of disease? Int J Epidemiol 32:1–22CrossRef

Didelez V, Sheehan N (2007) Mendelian randomization as an instrumental variable approach to causal inference. Stat Methods Med Res 16:309–330PubMedCrossRef

10.

Day N, Oakes S, Luben R et al (1999) EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 80(Suppl 1):95–103PubMed

11.

Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N (2004) Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 141:413–420PubMed

12.

McFadden E, Luben R, Wareham N, Bingham S, Khaw KT (2008) Occupational social class, educational level, smoking and body mass index, and cause-specific mortality in men and women: a prospective study in the European Prospective Investigation of Cancer and Nutrition in Norfolk (EPIC-Norfolk) cohort. Eur J Epidemiol 23:511–522PubMedCrossRef

13.

Wareham NJ, Jakes RW, Rennie KL et al (2003) Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) Study. Public Health Nutr 6:407–413PubMedCrossRef

14.

Patel PS, Sharp SJ, Luben RN et al (2009) Association between type of dietary fish and seafood intake and the risk of incident type 2 diabetes: the European prospective investigation of cancer (EPIC)-Norfolk cohort study. Diabetes Care 32:1857–1863PubMedCrossRef

15.

Kolz M, Johnson T, Sanna S et al (2009) Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 5:e1000504PubMedCrossRef

16.

Chien KL, Chen MF, Hsu HC et al (2008) Plasma uric acid and the risk of type 2 diabetes in a Chinese community. Clin Chem 54:310–316PubMedCrossRef

17.

Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC (2008) High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 31:361–362PubMedCrossRef

18.

Bhole V, Choi JW, Kim SW, de Vera M, Choi H (2010) Serum uric acid levels and the risk of type 2 diabetes: a prospective study. Am J Med 123:957–961PubMedCrossRef

19.

Altman DG, Bland JM (2003) Interaction revisited: the difference between two estimates. BMJ 326:219PubMedCrossRef

20.

Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K (2003) Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers. Eur J Epidemiol 18:523–530PubMedCrossRef

21.

Nakagawa T, Hu H, Zharikov S et al (2006) A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 290:F625–F631PubMedCrossRef

22.

Khosla UM, Zharikov S, Finch JL et al (2005) Hyperuricemia induces endothelial dysfunction. Kidney Int 67:1739–1742PubMedCrossRef

23.

Sautin YY, Nakagawa T, Zharikov S, Johnson RJ (2007) Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 293:C584–C596PubMedCrossRef

24.

Johnson RJ, Perez-Pozo SE, Sautin YY et al (2009) Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes? Endocr Rev 30:96–116PubMedCrossRef

25.

Perez-Pozo SE, Schold J, Nakagawa T, Sanchez-Lozada LG, Johnson RJ, Lillo JL (2010) Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response. Int J Obes (Lond) 34:454–461CrossRef

26.

George J, Carr E, Davies J, Belch JJ, Struthers A (2006) High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 114:2508–2516PubMedCrossRef

27.

Caulfield MJ, Munroe PB, O’Neill D et al (2008) SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 5:e197PubMedCrossRef

28.

Vitart V, Rudan I, Hayward C et al (2008) SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 40:437–442PubMedCrossRef

29.

McKeigue PM, Campbell H, Wild S et al (2010) Bayesian methods for instrumental variable analysis with genetic instruments (‘Mendelian randomization’): example with urate transporter SLC2A9 as an instrumental variable for effect of urate levels on metabolic syndrome. Int J Epidemiol 39:907–918PubMedCrossRef

30.

Stark K, Reinhard W, Grassl M et al (2009) Common polymorphisms influencing serum uric acid levels contribute to susceptibility to gout, but not to coronary artery disease. PLoS One 4:e7729PubMedCrossRef

31.

Yang Q, Kottgen A, Dehghan A et al (2010) Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet 3:523–530PubMedCrossRef

32.

Lin CS, Hung YJ, Chen GY et al (2011) A multicenter study of the association of serum uric acid, serum creatinine, and diuretic use in hypertensive patients. Int JCardiol 148:325–330CrossRef

33.

Villegas R, Xiang YB, Cai Q et al (2010) Prevalence and determinants of hyperuricemia in middle-aged, urban Chinese men. Metab Syndr Relat Disord 8:263–270PubMedCrossRef

34.

Wareham NJ, Rennie KL (1998) The assessment of physical activity in individuals and populations: why try to be more precise about how physical activity is assessed? Int J Obes Relat Metab Disord 22(Suppl 2):S30–S38PubMed

35.

Jonville-Bera AP, Saissi H, Bensouda-Grimaldi L et al (2009) Avoidability of adverse drug reactions spontaneously reported to a French regional drug monitoring centre. Drug Saf 32:429–440PubMedCrossRef

36.

Suzuki I, Yamauchi T, Onuma M, Nozaki S (2009) Allopurinol, an inhibitor of uric acid synthesis—can it be used for the treatment of metabolic syndrome and related disorders? Drugs Today (Barc) 45:363–378CrossRef

37.

Jordan KM, Cameron JS, Snaith M et al (2007) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 46:1372–1374CrossRef

38.

Dehghan A, Kottgen A, Yang Q et al (2008) Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 372:1953–1961PubMedCrossRef

39.

van der Harst P, Bakker SJ, de Boer RA et al (2010) Replication of the five novel loci for uric acid concentrations and potential mediating mechanisms. Hum Mol Genet 19:387–395PubMedCrossRef

40.

Bi M, Kao WH, Boerwinkle E et al (2010) Association of rs780094 in GCKR with metabolic traits and incident diabetes and cardiovascular disease: the ARIC Study. PLoS One 5:e11690PubMedCrossRef

41.

Yu KH, Luo SF, Tsai WP, Huang YY (2004) Intermittent elevation of serum urate and 24-hour urinary uric acid excretion. Rheumatology (Oxford) 43:1541–1545CrossRef

Titel: No evidence for a causal link between uric acid and type 2 diabetes: a Mendelian randomisation approach
verfasst von: R. Pfister
D. Barnes
R. Luben
N. G. Forouhi
M. Bochud
K.-T. Khaw
N. J. Wareham
C. Langenberg
Publikationsdatum: 01.10.2011
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 10/2011
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-011-2235-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

No evidence for a causal link between uric acid and type 2 diabetes: a Mendelian randomisation approach

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2011

Association of the SLC30A8 missense polymorphism R325W with proinsulin levels at baseline and after lifestyle, metformin or troglitazone intervention in the Diabetes Prevention Program

Additive effects of glycaemia and dyslipidaemia on risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register

Aliskiren reduces vascular pathology in diabetic retinopathy and oxygen-induced retinopathy in the transgenic (mRen-2)27 rat

Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice

Rat pancreatic level of cystathionine γ-lyase is regulated by glucose level via specificity protein 1 (SP1) phosphorylation

Hyperinsulinaemic hypoglycaemia and diabetes mellitus due to dominant ABCC8/KCNJ11 mutations

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin